Dube Eric M 4

What Happened
Eric M. Dube, CEO of Travere Therapeutics (TVTX), exercised a total of 60,000 stock options (coded M) and sold the 60,000 resulting shares in open-market transactions (coded S). On Jan 23, 2026 he exercised 8,135 options at $15.46/share (cost $125,767) and sold those 8,135 shares at about $30.01/share for $244,153. On Jan 27, 2026 he exercised 51,865 options at $15.46/share (cost $801,833) and sold those 51,865 shares at about $30.10/share for $1,560,981. Total cash paid to exercise: $927,600; total gross proceeds from sales: approximately $1,805,134. The filing also includes standard derivative-conversion reporting (zero-dollar derivative dispositions) reflecting the option-to-share conversions.

Key Details

• Transaction dates & prices:
  • 2026-01-23: Exercised 8,135 options @ $15.46 (acquired) and sold 8,135 shares @ ~$30.01 (proceeds $244,153).
  • 2026-01-27: Exercised 51,865 options @ $15.46 (acquired) and sold 51,865 shares @ ~$30.10 (proceeds $1,560,981).
• Totals: 60,000 options exercised, $927,600 paid to exercise, ~ $1.81M gross sale proceeds.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Notable footnotes:
  • Sale(s) were made pursuant to a written 10b5-1 trading plan adopted June 16, 2025 (F1).
  • Weighted-average sale-price details and price ranges provided in the filing (F2, F3).
  • Reported options were fully vested and exercisable (F4).
• Filing timeliness: Transactions occurred Jan 23 & Jan 27, 2026; the Form 4 was filed Jan 27, 2026 and was not reported as late.

Context

• This is an exercise of vested options followed by immediate open-market sales of the resulting shares (commonly a cashless exercise/sell). The presence of a 10b5-1 plan indicates the sales were preplanned and executed under that program. As always, sales by insiders can be routine (e.g., to cover exercise cost/taxes) and do not, by themselves, indicate the insider’s view of the company’s prospects.